Maarten van der Doelen

Chapter 5

Abiraterone and/or Enzalutamide 2 45 35 (77.8) 24 17 (70.8) 21 18 (85.7) 0.296 ‡ Abiraterone 45 31 (68.9) 24 13 (54.2) 21 18 (85.7) 0.028 ‡ Enzalutamide 45 11 (24.4) 24 9 (37.5) 21 2 (9.5) 0.040 ‡

Median number of therapies 45 2 [0-4] 24 2 [0-4] 21 2 [0-4] 0.744 None 45 6 (13.3) 24 5 (20.8) 21 1 (4.8) 0.193 ‡

Prior therapies for localized PCa Radical prostatectomy 1 45 10 (22.2) 24 4 (16.6) 21 6 (28.6) 0.476 ‡

Radiotherapy prostate (initial or salvage) 45 17 (37.8) 24 8 (33.3) 21 9 (42.9) 0.552 ‡ Pelvic lymph node dissection 45 11 (24.4) 24 6 (25.0) 21 5 (23.8) 1.000 ‡ Pelvic lymph node irradiation 45 4 (8.9) 24 1 (4.2) 21 3 (14.3) 0.326 ‡ Prior therapies for CRPC

injections (N=24) injections (N=21) P n

Time CRPC to radium-223 [mo] 45 23 [1-80] 24 20 [0-51] 21 30 [6-80] 0.082

Gleason score 8-10 45 27 (60.0) 24 16 (66.7) 21 11 (46.7) 0.329

Time diagnosis PCa to CRPC [mo] 45 29 [5-200] 24 30 [5-200] 21 26 [12-173] 0.716 Time start ADT to CRPC [mo] 45 22 [5-85] 24 20 [5-85] 21 24 [12-75] 0.539

Initial tumor stage Localized PCa 45 14 (31.1) 24 7 (29.2) 21 7 (33.3) 0.763

mean ± SD or n (% † ) n mean ± SD or n (% † ) n mean ± SD or n (% † ) Age [y] 45 71 [51-84] 24 71 [51-83] 21 70 [55-84] 0.666

Metastatic PCa 45 31 (68.9) 24 17 (70.8) 21 14 (66.7)

Group

median [range] or

6 radium-223

Group

median [range] or

1-5 radium-223

Complete cohort (N=45)

median [range] or

Table 1. Baseline patient characteristics.

140